Subtitle:

miR-122 silencing a novel therapy for HCV infections?

Publisher:

Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS

Description:

prace przeglądowe

Abstract:

Hepatitis C (HCV) infection is one of major epidemiological, medical and social concerns in the modern world. In Poland, around 700 000 people have HCV, worldwide the number is as high as 170-180 million. Current treatment consists of pegylated interferon-alpha and ribavirin, but is limited by the resistance of the viral strains, adverse effects, and high costs. Since HCV infection is a major cause of liver cirrhosis and hepatocellular carcinoma, it is necessary to develop novel antiviral compounds with improved virological response and reduced toxicity. In this article, we describe the results of recent trials to fight the HCV infection using an antagonising miR-122 oligo-LNA probe in primates.

Relation:

Biotechnologia, vol.90, 3 (2010)-.

Volume:

90

Issue:

3

Start page:

29

End page:

35

Detailed Resource Type:

Article

Format:

application/pdf

Resource Identifier:

oai:rcin.org.pl:71217 ; IChB B-85

Source:

Biblioteka Instytutu Chemii Bioorganicznej PAN

Language:

pol

Language of abstract:

eng

Temporal coverage:

2010

Rights:

Creative Commons Attribution BY-SA 4.0 license

Terms of use:

Copyright-protected material. [CC BY-SA 4.0] May be used within the scope specified in Creative Commons Attribution BY-SA 4.0 license, full text available at:

Digitizing institution:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Original in:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Projects co-financed by:

Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.

Access:

Open